Derivatives of the IL-2 receptor gamma chain, their production and use
View Patent ↗This invention relates to the use of the IL-2 common gamma (cγc) and related molecules for the modulation of signal activities controlled by NIK, and some new such molecules.
1. A method for the treatment of a disease involving the activity of NIK in the pathogenesis of said disease, said method comprising administration of a therapeutically effective amount of a polypeptide that binds to NIK, to a subject in need, wherein said polypeptide consists of:
(a) the intracellular domain of cγc (residues 284-369 SEQ ID NO: 22);
(b) a variant of (a) maintaining at least 95% identity with (a) and retaining the ability to bind NIK;
(c) a fragment of (a) or (b) that retains the ability to bind NIK and comprises the two proline residues at positions 360 and 361 of SEQ ID NO: 22; or
(d) a salt or functional derivative of (a), (b) or (c) that retains the ability to bind NIK, said functional derivative being an ester or aliphatic amide of the carboxyl group of the polypeptide or an N-acyl derivative of a free amino group of the polypeptide, or an O-acyl derivative of a free hydroxyl group of the polypeptide.
2. The method of claim 1 , wherein the polypeptide consists of 41MDD (residues 329-369 of SEQ ID NO: 22).
3. The method of claim 1 , wherein the polypeptide consists of ICDcγc (residues 284-369 of SEQ ID NO: 22).
4. The method of claim 1 , wherein the polypeptide consists of the polypeptide of residues 289-369 of SEQ ID NO: 22.
5. The method of claim 1 , wherein the polypeptide consists of the polypeptide of SEQ ID NO: 23.
6. The method of claim 1 , wherein the polypeptide consists of the polypeptide of SEQ ID NO: 25.
7. The method of claim 1 , wherein the polypeptide consists of the polypeptide of SEQ ID NO: 26.
8. The method of claim 1 , wherein the polypeptide consists of the polypeptide of SEQ ID NO: 27.